Inclusion Body Myositis (IBM) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 52 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Inclusion Body Myositis (IBM) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Inclusion Body Myositis (IBM) - Pipeline Review, H2 2014', provides an overview of the Inclusion Body Myositis (IBM)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis (IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inclusion Body Myositis (IBM) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Inclusion Body Myositis (IBM) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Inclusion Body Myositis (IBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inclusion Body Myositis (IBM)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Inclusion Body Myositis (IBM) Overview 6
Therapeutics Development 7
Pipeline Products for Inclusion Body Myositis (IBM) - Overview 7
Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis 8
Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies 9
Inclusion Body Myositis (IBM) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Inclusion Body Myositis (IBM) - Products under Development by Companies 12
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development 13
Acceleron Pharma, Inc. 13
New Zealand Pharmaceuticals Limited 14
Nobelpharma Co., Ltd. 15
Novartis AG 16
Ultragenyx Pharmaceutical Inc. 17
Inclusion Body Myositis (IBM) - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AAV1-FS-344 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ACE-083 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
aceneuramic acid - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
bimagrumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DEXM-74 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
UX-007 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Inclusion Body Myositis (IBM) - Recent Pipeline Updates 37
Inclusion Body Myositis (IBM) - Dormant Projects 44
Inclusion Body Myositis (IBM) - Product Development Milestones 45
Featured News & Press Releases 45
Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society 45
Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting 46
Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy 47
Oct 02, 2013: MorphoSys Collaborator to Start Pivotal Study with Bimagrumab 48
Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress 48
Aug 20, 2013: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) 49
Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy 49
Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2014 7
Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma, Inc., H2 2014 13
Inclusion Body Myositis (IBM) - Pipeline by New Zealand Pharmaceuticals Limited, H2 2014 14
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co., Ltd., H2 2014 15
Inclusion Body Myositis (IBM) - Pipeline by Novartis AG, H2 2014 16
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Inclusion Body Myositis (IBM) Therapeutics - Recent Pipeline Updates, H2 2014 37
Inclusion Body Myositis (IBM) - Dormant Projects, H2 2014 44